

In the Claims:

Claims 1-26 (Cancelled)

27. (Currently Amended): An isolated polypeptide comprising a member selected from the group consisting of

- (a) ~~an amino acid sequence matching SEQ ID NO:2 or SEQ ID NO:4 and~~
- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 contiguous amino acids ~~that matches an aligned contiguous segment of SEQ ID NO:2 or SEQ ID NO:4,~~

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide having the sequence of SEQ ID NO:2 ~~or SEQ ID NO:4.~~

28. (Cancelled)

29. (Previously Presented): The isolated polypeptide of claim 27, wherein the polypeptide is according to (a).

Claims 30-31 (Cancelled)

32. (Previously Presented): The isolated polypeptide of claim 27, wherein the polypeptide is according to (b).

33. (Cancelled)

34. (Previously Presented): The isolated polypeptide of claim 27, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.

35. (Currently Amended): The isolated polypeptide of claim 27, wherein the isolated polypeptide consists of SEQ ID NO:2 ~~or SEQ ID NO:4.~~

BEST AVAILABLE COPY

Claims 36-37 (Cancelled)

38. (Currently Amended): A fusion protein comprising the isolated polypeptide of Claim 27 ~~21~~.

Claims 39-42 (Cancelled)

43. (Currently Amended): An immunogenic composition ~~A vaccine~~ comprising the polypeptide of Claim 27 and a pharmaceutically acceptable carrier.

44. (Currently Amended): The immunogenic composition ~~vaccine~~ of Claim 43, wherein the immunogenic composition ~~vaccine~~ comprises at least one other *Moraxella catarrhalis* antigen.

45. (Cancelled)

46. (Previously Presented): A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 27.

Claims 47-49 (Cancelled)

50. (New): The isolated polypeptide of Claim 27, wherein the isolated polypeptide is an isolated, recombinant polypeptide.

51. (New): A fusion protein comprising the isolated polypeptide of Claim 50.

52. (New): An immunogenic composition comprising the polypeptide of Claim 50 and a pharmaceutically acceptable carrier.

53. (Previously Presented): A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 50.

54. (New): The isolated polypeptide of Claim 29, wherein the isolated polypeptide is an isolated, recombinant polypeptide.

55. (New): The isolated polypeptide of Claim 32, wherein the isolated polypeptide is an isolated, recombinant polypeptide.